KalVista's EKTERLY Launch Drives Revenue, But Losses Widen to $60M

TL;DR

**KalVista's first product revenue is a positive, but the massive jump in SG&A and widening losses mean this is a high-risk bet on EKTERLY's commercial success.**

AI Summary

KalVista Pharmaceuticals, Inc. reported a net loss of $60.096 million for the three months ended July 31, 2025, a significant increase from the $40.443 million net loss in the same period of 2024. This period marks the first time the company generated product revenue, totaling $1.426 million, following the FDA approval of EKTERLY (sebetralstat) on July 3, 2025, for hereditary angioedema (HAE). Operating expenses surged to $60.435 million from $44.215 million year-over-year, driven primarily by a substantial increase in selling, general and administrative (SG&A) expenses to $44.683 million from $17.601 million, reflecting commercialization efforts for EKTERLY. Research and development (R&D) expenses decreased to $15.162 million from $26.614 million. The company's cash and cash equivalents decreased to $124.304 million from $131.615 million, and total current assets fell to $205.896 million from $241.690 million as of April 30, 2025. KalVista anticipates continued losses as it commercializes EKTERLY and develops additional product candidates, but expects sufficient funding for at least the next twelve months based on current operating plans and existing capital resources of $191.5 million in cash, cash equivalents, and marketable securities.

Why It Matters

KalVista's successful FDA approval and initial revenue generation for EKTERLY is a critical milestone, transforming the company from a pure R&D entity to a commercial-stage biopharmaceutical firm. This shift could significantly impact investors, as future profitability hinges on EKTERLY's market penetration against existing HAE treatments, which previously required intravenous or subcutaneous administration. For patients, EKTERLY offers a novel oral on-demand option, potentially improving quality of life and treatment accessibility. Employees will see a focus shift towards commercial operations, while the broader market will watch how KalVista competes with established players in the HAE therapeutic space, potentially disrupting the competitive landscape.

Risk Assessment

Risk Level: high — The company reported an accumulated deficit of $713.3 million as of July 31, 2025, and a net loss of $60.096 million for the quarter. Selling, general and administrative expenses more than doubled to $44.683 million from $17.601 million year-over-year, indicating significant commercialization costs for EKTERLY, which could strain liquidity despite current funding projections.

Analyst Insight

Investors should closely monitor EKTERLY's sales trajectory and market adoption in upcoming quarters. Given the substantial increase in SG&A expenses and widening net loss, KalVista needs to demonstrate strong revenue growth to justify its commercialization investment. Consider this a speculative investment until a clear path to profitability emerges from EKTERLY's performance.

Financial Highlights

debt To Equity

N/A

revenue

$1.426M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

($60.096M)

eps

N/A

gross Margin

N/A

cash Position

$124.304M

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $1.426M — Product Revenue (First period generating product revenue, up from $0 in prior year.)
• ($60.096M) — Net Loss (Increased from ($40.443M) in the prior year, indicating widening losses.)
• $44.683M — Selling, General and Administrative Expenses (More than doubled from $17.601M, reflecting EKTERLY commercialization.)
• $15.162M — Research and Development Expenses (Decreased from $26.614M, indicating a shift in focus post-approval.)
• $713.3M — Accumulated Deficit (Increased from $653.170M, highlighting historical losses.)
• $191.5M — Cash, Cash Equivalents, and Marketable Securities (Provides liquidity for at least the next twelve months.)
• 50,523,274 — Common Stock Shares Outstanding (As of August 29, 2025.)
• $100.0M — ATM Shares Offering Price (Potential future equity financing capacity.)

Key Players & Entities

• KalVista Pharmaceuticals, Inc. (company) — registrant
• EKTERLY (company) — approved drug for HAE
• U.S. Food and Drug Administration (regulator) — approved EKTERLY on July 3, 2025
• TD Securities (USA) LLC (company) — sales agent for ATM Shares
• $60.096 million (dollar_amount) — net loss for the three months ended July 31, 2025
• $1.426 million (dollar_amount) — product revenue for the three months ended July 31, 2025
• $44.683 million (dollar_amount) — selling, general and administrative expenses for the three months ended July 31, 2025
• $15.162 million (dollar_amount) — research and development expenses for the three months ended July 31, 2025
• $713.3 million (dollar_amount) — accumulated deficit as of July 31, 2025
• $191.5 million (dollar_amount) — cash, cash equivalents and marketable securities as of July 31, 2025

FAQ

Risk Factors

• Sustained Net Losses and Cash Burn [high — financial]: The company reported a net loss of $60.096 million for the three months ended July 31, 2025, an increase from $40.443 million in the prior year. This trend is expected to continue due to commercialization efforts and ongoing development, impacting cash reserves.
• Commercialization Execution Risk [high — operational]: Successful commercialization of EKTERLY is critical. The significant increase in SG&A expenses to $44.683 million reflects these efforts, but market adoption, competition, and pricing pressures pose risks to revenue generation and profitability.
• Post-Approval Regulatory Scrutiny [medium — regulatory]: While EKTERLY received FDA approval, ongoing regulatory compliance, pharmacovigilance, and potential post-market studies are necessary. Any adverse events or manufacturing issues could lead to regulatory action.
• Dependence on Future Financing [medium — financial]: The company's cash position decreased to $124.304 million as of July 31, 2025. While management expects sufficient funding for at least 12 months, continued losses necessitate future capital raises, potentially through ATM offerings, which could dilute existing shareholders.
• Competition in HAE Market [medium — market]: The hereditary angioedema (HAE) market has existing treatments and potential new entrants. KalVista faces competition that could impact EKTERLY's market share and pricing power.
• R&D Pipeline Progression [low — operational]: Despite a shift in focus post-EKTERLY approval, the company continues R&D for other candidates. Delays or failures in these development programs could impact long-term growth prospects.

Industry Context

The biopharmaceutical industry, particularly in rare diseases like HAE, is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Companies like KalVista rely on successful drug approvals and effective commercialization strategies to achieve profitability. The market is competitive, with established players and emerging therapies vying for market share, often requiring substantial investment in sales and marketing post-approval.

Regulatory Implications

The FDA approval of EKTERLY signifies a major regulatory milestone, but ongoing compliance with manufacturing standards, post-market surveillance, and reporting requirements are critical. Any deviations could lead to warnings, fines, or product recalls, impacting revenue and reputation.

What Investors Should Do

1. Monitor SG&A Spending Efficiency
2. Evaluate Cash Burn Rate and Runway
3. Assess EKTERLY Market Adoption
4. Scrutinize R&D Pipeline Progress

Key Dates

• 2025-07-03: FDA Approval of EKTERLY (sebetralstat) — Marks the company's first product approval and entry into commercial revenue generation for the treatment of HAE.
• 2025-07-31: End of Second Quarter Fiscal Year 2026 — Reporting period for the 10-Q, showing initial product revenue and increased net loss due to commercialization expenses.
• 2025-08-29: Common Stock Shares Outstanding Date — Provides the current equity base of the company, relevant for per-share calculations and potential future dilution.

Glossary

EKTERLY (sebetralstat)

KalVista's first FDA-approved product for the treatment of hereditary angioedema (HAE). (The primary driver of new product revenue and significant increases in SG&A expenses.)

Hereditary Angioedema (HAE)

A rare genetic disorder characterized by recurrent episodes of severe swelling. (The target indication for EKTERLY, defining the market KalVista is entering.)

SG&A Expenses

Selling, General, and Administrative expenses, which include costs related to marketing, sales, and corporate operations. (These expenses surged to $44.683 million, reflecting the significant investment in commercializing EKTERLY.)

Accumulated Deficit

The cumulative net losses of a company since its inception. (Increased to $713.3 million, indicating a history of operating losses prior to and alongside the current commercialization phase.)

ATM Offering

At-The-Market offering, a method for public companies to sell shares over time directly into the existing stock market. (Represents a potential source of future financing, with an indicated offering price of $100.0 million, suggesting capacity for equity raises.)

Year-Over-Year Comparison

The current period shows a significant shift for KalVista, marked by the generation of $1.426 million in product revenue from EKTERLY following its July 2025 FDA approval. This contrasts sharply with the prior year's $0 product revenue. However, this transition has led to a substantial increase in the net loss to $60.096 million from $40.443 million, primarily driven by a more than doubling of SG&A expenses to $44.683 million for commercialization efforts. Concurrently, R&D expenses decreased, indicating a strategic pivot towards market launch.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share KALV The Nasdaq

Filing Documents

• kalv-20250731.htm (10-Q) — 1366KB
• kalv-ex31_1.htm (EX-31.1) — 19KB
• kalv-ex31_2.htm (EX-31.2) — 17KB
• kalv-ex32_1.htm (EX-32.1) — 12KB
• 0001193125-25-200757.txt ( ) — 6063KB
• kalv-20250731.xsd (EX-101.SCH) — 901KB
• kalv-20250731_htm.xml (XML) — 966KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations and Comprehensive Loss 4 Condensed Consolidated Statements of Changes in Stockholders' Equity 5 Condensed Consolidated Statements of Cash Flows 6 Notes to the Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 20 Item 4.

Controls and Procedures

Controls and Procedures 20

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 21 Item 1A.

Risk Factors

Risk Factors 21 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 21 Item 3. Defaults Upon Senior Securities 21 Item 4. Mine Safety Disclosures 21 Item 5. Other Information 21 Item 6. Exhibits 22

FINANCI AL INFORMATION

PART I. FINANCI AL INFORMATION

FINANCI AL STATEMENTS

Item 1. FINANCI AL STATEMENTS KalVista Pharmaceuticals, Inc. Condensed Consolidated Ba lance Sheets (in thousands, except share and per share amounts) July 31, April 30, 2025 2025 (Unaudited) Assets Current assets: Cash and cash equivalents $ 124,304 $ 131,615 Marketable securities 67,161 89,002 Accounts receivable, net 1,926 - Research and development tax credit receivable 561 1,383 Prepaid expenses and other current assets 11,944 19,690 Total current assets 205,896 241,690 Property and equipment, net of accumulated depreciation of $ 4,925 and $ 4,747 2,067 1,988 Right of use assets 5,165 5,544 Other assets 2,377 1,548 Total assets $ 215,505 $ 250,770 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 5,869 $ 4,883 Accrued expenses 18,971 27,307 Lease liability - current portion 2,122 1,977 Deferred revenue 11,413 11,000 Total current liabilities 38,375 45,167 Long-term liabilities: Lease liability - net of current portion 4,019 4,330 Royalty obligation 132,321 105,882 Total long-term liabilities 136,340 110,212 Stockholders' equity Common stock, $ 0.001 par value, 100,000,000 authorized Shares issued and outstanding: 50,339,823 at July 31, 2025 and 49,762,048 at April 30, 2025 50 50 Additional paid-in capital 760,393 753,725 Accumulated deficit ( 713,266 ) ( 653,170 ) Accumulated other comprehensive loss ( 6,387 ) ( 5,214 ) Total stockholders' equity 40,790 95,391 Total liabilities and stockholders' equity $ 215,505 $ 250,770 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 KalVista Pharmaceuticals, Inc. Condensed Consolidated Statements of Opera tions and Comprehensive Loss (in thousands, except share and per share amounts) (Unaudited) Three Months Ended July 31, 20

View Full Filing

View this 10-Q filing on SEC EDGAR